Subcutaneous drug delivery and the role of the lymphatics
- PMID: 24981760
- DOI: 10.1016/j.ddtec.2005.05.006
Subcutaneous drug delivery and the role of the lymphatics
Abstract
Subcutaneous injections are widely utilised as a delivery route for compounds with limited oral bioavailability or as a means to modify or extend the release profile. In this review, factors affecting absorption from the subcutaneous space are discussed with particular emphasis on differential drug absorption into either the underlying blood or lymphatic capillaries. Formulation and targeted delivery approaches, which utilise the subcutaneous administration route, are reviewed with reference to associated technologies and future challenges.:
© 2005 Elsevier Ltd . All rights reserved.
Similar articles
-
The antibody drug absorption following subcutaneous or intramuscular administration and its mathematical description by coupling physiologically based absorption process with the conventional compartment pharmacokinetic model.J Clin Pharmacol. 2013 Mar;53(3):314-25. doi: 10.1002/jcph.4. Epub 2013 Feb 20. J Clin Pharmacol. 2013. PMID: 23426855
-
Lymphatic transport and catabolism of therapeutic proteins after subcutaneous administration to rats and dogs.Drug Metab Dispos. 2012 May;40(5):952-62. doi: 10.1124/dmd.111.043604. Epub 2012 Feb 10. Drug Metab Dispos. 2012. PMID: 22328584
-
Diverse approaches for the enhancement of oral drug bioavailability.Biopharm Drug Dispos. 2011 May;32(4):185-209. doi: 10.1002/bdd.750. Epub 2011 Apr 7. Biopharm Drug Dispos. 2011. PMID: 21480294 Review.
-
Palatal mucosa as a route for systemic drug delivery: A review.J Control Release. 2011 Apr 10;151(1):2-9. doi: 10.1016/j.jconrel.2010.11.003. Epub 2010 Nov 6. J Control Release. 2011. PMID: 21059376 Review.
-
Lymphatic absorption is the primary contributor to the systemic availability of epoetin Alfa following subcutaneous administration to sheep.J Pharmacol Exp Ther. 2005 Apr;313(1):345-51. doi: 10.1124/jpet.104.078790. Epub 2004 Dec 3. J Pharmacol Exp Ther. 2005. PMID: 15579493
Cited by
-
Durable cross-protective neutralizing antibody responses elicited by lipid nanoparticle-formulated SARS-CoV-2 mRNA vaccines.NPJ Vaccines. 2024 Feb 23;9(1):43. doi: 10.1038/s41541-024-00835-x. NPJ Vaccines. 2024. PMID: 38396073 Free PMC article.
-
Leveraging Lymphatic System Targeting in Systemic Lupus Erythematosus for Improved Clinical Outcomes.Pharmacol Rev. 2024 Feb 13;76(2):228-250. doi: 10.1124/pharmrev.123.000938. Pharmacol Rev. 2024. PMID: 38351070 Review.
-
Nanoparticle-Conjugated Toll-Like Receptor 9 Agonists Improve the Potency, Durability, and Breadth of COVID-19 Vaccines.ACS Nano. 2024 Jan 30;18(4):3214-3233. doi: 10.1021/acsnano.3c09700. Epub 2024 Jan 12. ACS Nano. 2024. PMID: 38215338 Free PMC article.
-
Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial.Nat Med. 2024 Feb;30(2):531-542. doi: 10.1038/s41591-023-02760-3. Epub 2024 Jan 9. Nat Med. 2024. PMID: 38195752 Free PMC article. Clinical Trial.
-
25 years of biologic DMARDs in rheumatology.Nat Rev Rheumatol. 2023 Dec;19(12):761-766. doi: 10.1038/s41584-023-01036-x. Epub 2023 Nov 2. Nat Rev Rheumatol. 2023. PMID: 37919339 No abstract available.
LinkOut - more resources
Full Text Sources
Other Literature Sources